Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma
Molecular Cell · 2025-04 · 85 (7) · 1311-1329.e16
DOI: 10.1016/j.molcel.2025.03.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Cell, 2025-04. Verfasst von John L Pulice und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Biological and Biomedical Sciences Program,…. Hauptthemen laut MEDLINE: Thyroid Nuclear Factor 1, Lung Neoplasms, Adenocarcinoma of Lung, Gene Dosage. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
Amplification-mediated oncogene overexpression is a critical and widespread driver event in cancer, yet our understanding of how amplification and dosage mediate oncogene regulation is limited. Here, we find that the most significant focal amplification event in lung adenocarcinoma (LUAD) targets a lineage "super-enhancer" near the NKX2-1 lineage transcription factor. The NKX2-1 super-enhancer is targeted by focal and co-amplification with NKX2-1 and controls NKX2-1 expression and regulation. We find that NKX2-1 directly controls enhancer accessibility to drive a lineage-addicted state in LUAD. We precisely map the effects of NKX2-1 dosage modulation upon both overexpression and knockdown and identify both linear and non-linear regulation by NKX2-1 dosage. We find that NKX2-1 is a widespread dependency in LUAD cell lines and that NKX2-1 confers persistence to EGFR inhibitors. Our data suggest a defining role for dosage in the oncogenic regulation of amplified NKX2-1 and that amplified NKX2-1 lineage addiction defines LUAD tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Biological and Biomedical Sciences Program, Harvard University, Cambridge, MA, USA; Cancer Program, Broad Institu…
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Genetics, Harvard Medical S…
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- National Institutes of Health National Cancer Institute
- National Defense Science and Engineering Graduate
Zitieren
APA
Pulice, J. L., & Meyerson, M. (2025). Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. Molecular Cell, 85(7), 1311-1329.e16. https://doi.org/10.1016/j.molcel.2025.03.001
Vancouver
Pulice JL, Meyerson M. Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. Molecular Cell. 2025;85(7):1311-1329.e16. doi:10.1016/j.molcel.2025.03.001
BibTeX
@article{Pulice2025,
author = {Pulice, John L and Meyerson, Matthew},
title = {Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma},
journal = {Molecular Cell},
year = {2025},
volume = {85},
number = {7},
pages = {1311--1329.e16},
doi = {10.1016/j.molcel.2025.03.001}
}
EUVIMED